Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

What Happened? A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes ...

(Reuters) -Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a potential sale, and warned it could launch a proxy fight if no ...

Shares of Novavax Inc. NVAX slipped 6.13% to $8.42 Thursday, on what proved to be an all-around dismal trading session for ...

In addition to Bank of America Securities, Novavax also received a Sell from Citi’s Geoff Meacham in a report issued on January 30. However, on February 3, TipRanks – Google reiterated a Hold rating ...

(Reuters) -Novavax on Thursday provided preliminary adjusted revenue for 2026 and pushed back its profitability target by a year to 2028 as the biotech awaits key product launches from its partnership ...

Under the non-exclusive agreement, Pfizer will utilize Novavax’s Matrix-M adjuvant in products across two disease areas, with Novavax receiving a $30 million upfront payment. Additionally, the ...

Novavax, Inc. (NASDAQ: NVAX) shares are trading higher Tuesday after the company announced it entered into a license agreement with Pfizer, Inc. (NYSE: PFE) for use of its Matrix-M adjuvant. Under the ...

Novavax (NVAX) shares added ~5% in the premarket on Tuesday after the COVID-19 vaccine maker reached a licensing deal with Pfizer (PFE) regarding the use of its Matrix-M adjuvant in the New York-based ...

Shares of Novavax Inc. NVAX slid 1.19% to $8.27 Wednesday, on what proved to be an all-around mixed trading session for the ...